Pharmaceutical News

RSS

Obesity, contraceptives pills may increase risk of developing MS in later stages, says study

The role of the so-called "obesity hormone" leptin and hormones used for birth control in the development of multiple sclerosis (MS) is examined in two new studies released today that will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

28 Feb 2014

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

28 Feb 2014

Vaccine targeting tumors could initiate immune response to fight cancer

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

28 Feb 2014

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds.

27 Feb 2014

Study raises concerns about use of acetaminophen during pregnancy

Acetaminophen, found in over-the-counter products such as Excedrin and Tylenol, provides many people with relief from headaches and sore muscles. When used appropriately, it is considered mostly harmless. Over recent decades, the drug, which has been marketed since the 1950s, has become the medication most commonly used by pregnant women for fevers and pain.

27 Feb 2014

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Patients were twice as likely to have a diabetic foot ulcer heal within eight weeks when they were treated with a tissue repair drug versus a placebo, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

27 Feb 2014

Researchers discover new target for human antibodies that holds key to vaccine for dengue

Creating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Carolina have discovered a new target for human antibodies that could hold the key to a vaccine for the world's most widespread mosquito-borne disease.

27 Feb 2014

Somali Americans develop twice antibody response to rubella from current vaccine

Somali Americans develop twice the antibody response to rubella from the current vaccine compared to Caucasians in a new Mayo Clinic study on individualized aspects of immune response.

27 Feb 2014

Goal: Therapies for hearing loss and communications problems

Research scientist Christine Portfors will study how the brain chemical dopamine influences hearing with support from the National Institutes of Health. The work may ultimately lead to better therapies for people with hearing loss and communication problems.

27 Feb 2014

Anika Therapeutics receives marketing approval from FDA for MONOVISC injection

Anika Therapeutics, Inc. today announced it has received marketing approval for MONOVISC from the U.S. Food and Drug Administration. MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering from osteoarthritis (OA) of the knee.

26 Feb 2014

Prothelia and University of Nevada, Reno enter into agreements with Alexion for development of Laminin-111

Prothelia Incorporated (Prothelia) and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.

26 Feb 2014

ViroXis signs agreement with global pharmaceutical for marketing of OTC sandalwood oil-containing product

ViroXis Corporation is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of an over-the-counter (OTC) sandalwood oil-containing product.

26 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Santalis Pharmaceuticals Inc., a joint venture with TFS Corporation Ltd., of Australia (ASX: TFC) is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of a number of over-the-counter (OTC) dermatology products containing TFS' sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO).

26 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

Children of women who used acetaminophen during pregnancy appear to be at higher risk for ADHD

Children of women who used the pain reliever acetaminophen (paracetamol) during pregnancy appear to be at higher risk for attention-deficit/hyperactivity disorder (ADHD)-like behavioral problems and hyperkinetic disorders.

26 Feb 2014

U.S study:10% of non-lifetime marijuana users report that they would try marijuana if legal

National support for marijuana ("cannabis") legalization is increasing in the United States (US). Recreational use was recently legalized in the states of Colorado and Washington; other states across the country are expected to follow suit.

26 Feb 2014

Study shows psychological, interpersonal effects of antidepressants have reached bizarre levels

A University of Liverpool researcher has shown that thoughts of suicide, sexual difficulties and emotional numbness as a result of anti-depressants may be more widespread than previously thought.

26 Feb 2014

Murad launches Acne Spot Fast Fix and Acne Clearing Solution

Murad, Inc., the skincare brand synonymous with high-performance, science-based products, announced today the addition of two new products, Acne Spot Fast Fix and Acne Clearing Solution, which are proven to enhance the effectiveness of the company's already award-winning Acne line.

25 Feb 2014

New report reveals prevalence of heroin-related overdose deaths in Kentucky

A new report from the Kentucky Injury Prevention and Research Center (KIPRC) reveals the prevalence and charges associated with drug overdose in the Bluegrass state.

25 Feb 2014

Pharmaceutical News

Obesity, contraceptives pills may increase risk of developing MS in later stages, says study

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Vaccine targeting tumors could initiate immune response to fight cancer

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Study raises concerns about use of acetaminophen during pregnancy

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Researchers discover new target for human antibodies that holds key to vaccine for dengue

Somali Americans develop twice antibody response to rubella from current vaccine

Goal: Therapies for hearing loss and communications problems

Anika Therapeutics receives marketing approval from FDA for MONOVISC injection

Prothelia and University of Nevada, Reno enter into agreements with Alexion for development of Laminin-111

ViroXis signs agreement with global pharmaceutical for marketing of OTC sandalwood oil-containing product

FDA approves KALYDECO for people with cystic fibrosis

Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Children of women who used acetaminophen during pregnancy appear to be at higher risk for ADHD

U.S study:10% of non-lifetime marijuana users report that they would try marijuana if legal

Study shows psychological, interpersonal effects of antidepressants have reached bizarre levels

Murad launches Acne Spot Fast Fix and Acne Clearing Solution

New report reveals prevalence of heroin-related overdose deaths in Kentucky

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News